Opendata, web and dolomites

RESCUER SIGNED

RESISTANCE UNDER COMBINATORIAL TREATMENT IN ER+ AND ER- BREAST CANCER.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESCUER project word cloud

Explore the words cloud of the RESCUER project. It provides you a very rough idea of what is the project "RESCUER" about.

ongoing    therapies    resistance    exploring    animal    bc    combinations    heterogeneity    multidimensional    ethical    benefit    death    organ    strata    tumor    women    despite    vivo    cancer    tested    patients    treatment    administering    thin    tried    drugs    data    omics    overreaching    responders    probability    sub    gather    network    solid    effectiveness    drug    breast    approved    physiological    discover    molecular    cellular    model    mechanisms    stratification    clinical    biological    everyone    personalized    optimization    signatures    curative    combine    subtypes    omic    trials    algorithms    therapy    framework    efficient    first    integrate    aspects    endowed    predict    xenograft    computer    classified    alternative    combination    few    ex    models    actually    ethics    frameworks    vs    worldwide    longitudinal    individual    computational    degree    samples    newly    combinatorial    arbitrary    indication    purpose    silico    patient   

Project "RESCUER" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITETET I OSLO 

Organization address
address: PROBLEMVEIEN 5-7
city: OSLO
postcode: 313
website: www.uio.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 6˙283˙250 €
 EC max contribution 6˙000˙000 € (95%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITETET I OSLO NO (OSLO) coordinator 933˙543.00
2    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 946˙443.00
3    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 935˙625.00
4    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 466˙337.00
5    VIB BE (ZWIJNAARDE - GENT) participant 464˙375.00
6    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 424˙781.00
7    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 400˙000.00
8    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 389˙012.00
9    INTERDISCIPLINARY CENTER (IDC) HERZLIYA IL (HERZLIYA) participant 371˙875.00
10    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 273˙000.00
11    UNIVERSITATSKLINIKUM ERLANGEN DE (ERLANGEN) participant 245˙712.00
12    INSTITUT FUR FRAUENGESUNDHEIT GMBH DE (ERLANGEN) participant 141˙293.00
13    RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY US (NEW BRUNSWICK) participant 8˙000.00
14    NANTOMICS LLC US (DOVER) participant 0.00
15    NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU NO (TRONDHEIM) participant 0.00

Map

 Project objective

Breast Cancer (BC) is the first cause of cancer-related death in women worldwide. Breast cancer is classified into well-recognized molecular subtypes. Despite solid pre-clinical evidence, only some patients benefit from administering drug combinations, an indication that patient and tumor heterogeneity is still present in the current stratification. Out of the numerous possible combinations of approved drugs, only a few have been actually tried, and the choice of tested combinations has been to some degree arbitrary. This proposal seeks to develop new approaches and identify mechanisms of treatment resistance at systems level, exploring how the effectiveness of specific targeted therapies applied in different clinical trials is affected by patient- and tumor-specific conditions. For this purpose, the project will gather and integrate longitudinal multidimensional data from ongoing clinical trials and newly generated --omics using systems approaches, which combine sub-cellular/cellular and/or organ level in-silico models and network analysis to build computational frameworks able to discover molecular signatures of resistance and predict patient response to combinatorial therapies. We aim to identify the physiological characteristics of non-responders vs. responders from existing and newly generated multi-omic data and biological samples from in-vivo and ex-vivo clinical studies of specific subtypes of BC patients treated with combination therapy. This new knowledge will be used to investigate the curative potential of new personalized drugs combinations. The overreaching goal is to develop computer “xenograft model” as a cost-efficient and better alternative in terms of ethics, availability to everyone, and animal use. The framework will include optimization algorithms to identify combinations of approved drugs with a high probability to work on individual or thin strata of patients. The project is endowed with a “legal” framework addressing ethical aspects

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESCUER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESCUER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ENDpoiNTs (2019)

Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental NeuroToxicity

Read More  

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More